CRISPR-Cas9 targeting of telomeric variant repeats induces selective lethality in ALT-positive cancer cells

The technique deploys a guide RNA library against repetitive sequences enriched in alternative lengthening of telomeres (ALT) tumors. Delivery via lipid nanoparticles or AAV produced double-strand breaks that collapsed replication forks and activated p53-independent death pathways. In PDX models of osteosarcoma and glioblastoma, tumor volume reduction reached 70% at 28 days with no measurable off-target editing at 200x coverage whole-genome sequencing.

Standard CRISPR oncology coverage emphasizes delivery or editing efficiency. This work instead exploits a structural vulnerability present only in ALT cells: the abundance of non-canonical telomeric DNA. Earlier ALT inhibitors (ATR, BLM) showed narrower therapeutic indices and rapid resistance; the CRISPR approach bypasses enzymatic targets entirely. The IGI report omits direct comparison to prior ALT papers in Nature Communications 2022 and Cell Reports 2023 that mapped C-circle dependency.

Operational translation requires repeated in vivo dosing and control of innate immune activation. Manufacturing of guide RNA cocktails at GMP scale remains unproven at the diversity needed to cover patient-specific ALT variants. IND-enabling toxicology packages are expected to begin in 2025.